Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
- 13 February 2019
- journal article
- research article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 202, 91-99
- https://doi.org/10.1016/j.ajo.2019.02.005
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Regeneron
- Genentech
- Roche
- Ophthotech
- Santen
- National Eye Institute (P30-EY006360)
- National Institute of Neurological Disorders and Stroke (R01-NS089694)
- Genentech (ML28724)
This publication has 22 references indexed in Scilit:
- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend ProtocolOphthalmology, 2015
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial ResultsOphthalmology, 2014
- Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laserClinical Ophthalmology, 2013
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Does Laser Still Have a Role in the Management of Retinal Vascular and Neovascular Diseases?American Journal of Ophthalmology, 2011
- Clinical Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILASOphthalmology, 2011
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- Macular Grid PhotocoagulationAmerican Journal of Ophthalmology, 1988